JP Morgan Call 155 CHKP 21.06.202.../ DE000JK79BX9 /
| 6/14/2024 12:50:13 PM | Chg.-0.130 | Bid3:43:10 PM | Ask3:43:10 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 0.300EUR | -30.23% | 0.330 Bid Size: 30,000 |
0.350 Ask Size: 30,000 |
Check Point Software... | 155.00 USD | 6/21/2024 | Call |
GlobeNewswire
3:30 PM
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon...
GlobeNewswire
2:00 PM
ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritini...
GlobeNewswire
1:30 PM
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective an...
GlobeNewswire
1:00 PM
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-3...
GlobeNewswire
12:00 PM
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Tria...
GlobeNewswire
6/12
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at ...
GlobeNewswire
6/12
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...
GlobeNewswire
6/12
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck ...
GlobeNewswire
6/11
Check Point Software Simplifies Cloud Application Security with AI-Powered WAFaaS
GlobeNewswire
6/11
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-I...
GlobeNewswire
6/10
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
6/10
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FD...
GlobeNewswire
6/6
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Reco...
GlobeNewswire
6/6
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European...
GlobeNewswire
6/6
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Beha...
GlobeNewswire
6/5
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positiv...
GlobeNewswire
6/5
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
6/4
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losse...
GlobeNewswire
6/4
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
GlobeNewswire
6/4
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investor...
GlobeNewswire
6/3
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewswire
6/3
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the...
